(Q44319755)

1 December 2017

Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib (English)

1 reference

1 December 2017

0 references

P Meeus

1

1 reference

1 December 2017

H Demuynck

2

1 reference

1 December 2017

Ph Martiat

3

1 reference

1 December 2017

L Michaux

4

1 reference

1 December 2017

E Wouters

5

1 reference

1 December 2017

A Hagemeijer

6

1 reference

1 December 2017

1 February 2003

1 reference

1 December 2017

1 reference

1 December 2017

17

1 reference

1 December 2017

2

1 reference

1 December 2017

465-467

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402791

1 December 2017

0 references

cites work

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402791

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402791

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402791

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402791

Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402791

21 January 2018

Identifiers

DOI

10.1038/SJ.LEU.2402791

1 reference

Dimensions Publication ID

1 December 2017

0 references

1 reference